STAAR Surgical Co
NASDAQ:STAA

Watchlist Manager
STAAR Surgical Co Logo
STAAR Surgical Co
NASDAQ:STAA
Watchlist
Price: 19.65 USD 7.14% Market Closed
Market Cap: 968.4m USD
Have any thoughts about
STAAR Surgical Co?
Write Note

STAAR Surgical Co
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

STAAR Surgical Co
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
STAAR Surgical Co
NASDAQ:STAA
Cash from Operating Activities
$15.7m
CAGR 3-Years
-29%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Cash from Operating Activities
$129.2m
CAGR 3-Years
7%
CAGR 5-Years
0%
CAGR 10-Years
0%
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Cash from Operating Activities
$461m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Align Technology Inc
NASDAQ:ALGN
Cash from Operating Activities
$738.2m
CAGR 3-Years
-14%
CAGR 5-Years
0%
CAGR 10-Years
13%
Lantheus Holdings Inc
NASDAQ:LNTH
Cash from Operating Activities
$544.8m
CAGR 3-Years
116%
CAGR 5-Years
47%
CAGR 10-Years
47%
Merit Medical Systems Inc
NASDAQ:MMSI
Cash from Operating Activities
$220.8m
CAGR 3-Years
14%
CAGR 5-Years
23%
CAGR 10-Years
15%
No Stocks Found

STAAR Surgical Co
Glance View

Market Cap
968.3m USD
Industry
Health Care

In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures. STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.

STAA Intrinsic Value
14.54 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is STAAR Surgical Co's Cash from Operating Activities?
Cash from Operating Activities
15.7m USD

Based on the financial report for Dec 27, 2024, STAAR Surgical Co's Cash from Operating Activities amounts to 15.7m USD.

What is STAAR Surgical Co's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-9%

Over the last year, the Cash from Operating Activities growth was 8%. The average annual Cash from Operating Activities growth rates for STAAR Surgical Co have been -29% over the past three years , -9% over the past five years .

Back to Top